KOREA WHO
-
-
Chairman and CEO of Jetema
Kim Jae-young
Korea’s Filler Pioneer Boosts Jetema Toxin Push
-
Last Updated on Jan 10, 2026
-
Chairman and CEO of Jetema
Copy Url : https://www.koreawho.com/profile/KimJaeyoung- Life Summary
Kim Jae-young is the CEO of Jetema.
He was born on August 5, 1968.
He graduated from the College of Pharmacy at Kyung Hee University and earned a Ph.D. in biomedical engineering at Kyung Hee University.
As part of the first generation in Korea’s filler and biopharmaceutical industry, he co-founded HLVS (Humedics), a domestic filler manufacturer.
He later joined Jetema, a developer and producer of hyaluronic acid fillers and botulinum toxin products, and went on to lead the company.
He led business expansion and facility investment, including the acquisition of Human Medical and the establishment of a dedicated hyaluronic acid filler plant.
He has a strong interest in bone growth factors and is focusing on diversifying the business portfolio and expanding global operations.
#Jetema #KimJaeyoung #biomedicalengineering #hyaluronicacid #fillerindustry #botulinumtoxin #biopharmaceuticals #M&A #globalexpansion #Kbio
He was born on August 5, 1968.
He graduated from the College of Pharmacy at Kyung Hee University and earned a Ph.D. in biomedical engineering at Kyung Hee University.
As part of the first generation in Korea’s filler and biopharmaceutical industry, he co-founded HLVS (Humedics), a domestic filler manufacturer.
He later joined Jetema, a developer and producer of hyaluronic acid fillers and botulinum toxin products, and went on to lead the company.
He led business expansion and facility investment, including the acquisition of Human Medical and the establishment of a dedicated hyaluronic acid filler plant.
He has a strong interest in bone growth factors and is focusing on diversifying the business portfolio and expanding global operations.
#Jetema #KimJaeyoung #biomedicalengineering #hyaluronicacid #fillerindustry #botulinumtoxin #biopharmaceuticals #M&A #globalexpansion #Kbio
- Life Summary
- Career Highlights & Challenges
- · Leading the Aesthetic Market with Toxins, Fillers and Lifting Threads
- · Jetema’s Governance Structure
- · 2025 Q3 Revenue and Operating Profit Surge
- · 110 Billion KRW Convertible Bonds Repaid Early
- · Latin America Academic Symposium Held
- · JTM201 U.S. Phase 2 Trial Shows 81.1% Efficacy and Rapid Onset
- · Fostering Bio-Aesthetic Startups Through Gangwon CCEI Partnership
- · Penetrating Japan’s Aesthetic Market Through ASLS Tokyo 2025
- · Targeting the KRW 10 Trillion U.S. MedSpa Market
- · Accelerating Eastern European Expansion with Bulgaria Brand Launch
- · PCT Patent Filed for Next-Generation Liquid Toxin Technology Maximizing Ease of Use
- · Targeting KRW 100 Billion in Sales Through Toxin and China Filler Expansion
- · Faster Execution of KRW 1 Trillion Toxin Pre-Export Contracts, Strong Expectations for Türkiye Market
- · Decision for 100% Bonus Issue Granting One New Share per Common Share to Enhance Shareholder Value
- · ‘Jetema The Toxin Inj.’ Receives Official Product Approval After Four-Year Wait
- · Jetema’s Journey
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos